<DOC>
	<DOC>NCT01199068</DOC>
	<brief_summary>The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with erlotinib.</brief_summary>
	<brief_title>CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Efatutazone</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically or cytologically confirmed unresectable locally advanced or metastatic (stage IIIb or IV) Nonsmall Cell Lung Cancer (NSCLC) Recurrent disease (either no response to treatment or subsequent relapse after an objective response) that has progressed after firstline platinum based therapy Male or female ≥ 18 years of age Anticipation of more than 3 months survival Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1 Adequate organ and bone marrow function Prior Tyrosine Kinase Inhibitor (TKI) therapy Anticipation of need for a major surgical procedure or radiation therapy during the study Remaining influence of previous therapies such as radiotherapy, surgery, immunotherapy within 4 weeks prior to start of study treatment Treatment with anticancer medication within 4 weeks before study treatment, currently enrolled in another investigational drug study, or enrolled in another investigational drug study within 4 weeks of start of treatment History of any of the following events within 6 months prior to start of study treatment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class ≥I Congestive Heart Failure (CHF), cerebrovascular accident or cerebral infarction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event; clinically significant pulmonary disease (eg, severe ChronicObstructive Pulmonary Disease (COPD) or asthma) Severe edema, ascites fluid, pericardial or pleural effusion or pericardial involvement with the tumor within 6 months prior to start of study treatment, or which require steroid therapy/ diuretic therapy Subjects with brain metastasis (defined as untreated, symptomatic or requiring steroids or anticonvulsant medications to control associated symptoms) Subjects with clinically significant active infection which requires antibiotic therapy, or who are hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)positive or receiving antiretroviral therapy Subjects with malabsorption syndrome, chronic diarrhea (lasting over 4 weeks), inflammatory bowel disease, or partial bowel obstruction Diabetes mellitus requiring insulin, or a history of poor serum glucose control with the use of noninsulin diabetes medications Treatment with Thiazolidinedione(TZDs) within 4 weeks prior to start of study treatment History of a second malignancy, with the exception of in situ cervical cancer or adequately treated basal cell or squamous cell carcinoma of the skin Poorlycontrolled blood pressure as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>PPAR gamma agonist</keyword>
	<keyword>Tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Antineoplastic Agent</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Neoplasms</keyword>
</DOC>